Nom du produit:2,3-Difluoropyridine

IUPAC Name:2,3-difluoropyridine

CAS:1513-66-2
Formule moléculaire:C5H3F2N
Pureté:98%
Numéro de catalogue:CM120583
Poids moléculaire:115.08

Unité d'emballage Stock disponible Prix($) Quantité
CM120583-100g in stock ŤŤŮ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1513-66-2
Formule moléculaire:C5H3F2N
Point de fusion:-
Code SMILES:FC1=CC=CN=C1F
Densité:
Numéro de catalogue:CM120583
Poids moléculaire:115.08
Point d'ébullition:
N° Mdl:MFCD04114143
Stockage:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

NST-628
Nested Therapeutics’ lead program, NST-628, is an oral, brain-penetrant pan-RAF-MEK non-degrading molecular glue that lacks paradoxical pathway activation through the prevention of RAF paralog heterodimerization. By inhibiting the phosphorylation and activation of MEK by RAF, NST-628 targets a critical step in the RAS/RAF/MAPK signaling pathway. Preclinically, NST-628 results in broad efficacy, high tolerability, CNS activity across various RAS- and RAF-driven tumor models, and has the potential to deliver transformative clinical benefits both as a monotherapy and as a key component in combination therapies. Now, NST-628 has advanced to a Ph. I trial in patients with refractory MAPK pathway mutated/dependent advanced solid tumors.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products